Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Silgan Holdings (SLGN) Cash & Equivalents (2016 - 2025)

Historic Cash & Equivalents for Silgan Holdings (SLGN) over the last 17 years, with Q3 2025 value amounting to $389.2 million.

  • Silgan Holdings' Cash & Equivalents rose 560.72% to $389.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $389.2 million, marking a year-over-year increase of 560.72%. This contributed to the annual value of $822.9 million for FY2024, which is 2798.64% up from last year.
  • Per Silgan Holdings' latest filing, its Cash & Equivalents stood at $389.2 million for Q3 2025, which was up 560.72% from $317.5 million recorded in Q2 2025.
  • In the past 5 years, Silgan Holdings' Cash & Equivalents registered a high of $822.9 million during Q4 2024, and its lowest value of $164.8 million during Q2 2021.
  • Its 5-year average for Cash & Equivalents is $376.0 million, with a median of $308.6 million in 2024.
  • As far as peak fluctuations go, Silgan Holdings' Cash & Equivalents crashed by 6907.66% in 2021, and later surged by 9303.91% in 2023.
  • Over the past 5 years, Silgan Holdings' Cash & Equivalents (Quarter) stood at $631.4 million in 2021, then dropped by 7.26% to $585.6 million in 2022, then increased by 9.78% to $642.9 million in 2023, then grew by 27.99% to $822.9 million in 2024, then tumbled by 52.7% to $389.2 million in 2025.
  • Its Cash & Equivalents stands at $389.2 million for Q3 2025, versus $317.5 million for Q2 2025 and $353.0 million for Q1 2025.